FDA inspection
Marksans Pharma Limited: FDA inspection ending Jun 25, 2014
FDA inspection 884694 · Administrative/Directed Change (ADC) · Vasco Da Gama
Key facts
| Inspection ID | 884694 |
|---|---|
| Firm | Marksans Pharma Limited |
| FEI number | 3006230648 |
| Address | & L - 83 Plot No L - 82, Verna |
| City | Vasco Da Gama |
| Fiscal year | 2014 |
| Inspection end date | Jun 25, 2014 |
| Classification | Administrative/Directed Change (ADC) |
| Project area | Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs |
| Product type | Drugs |
At a glance
- None Citations
- None Posted citations
- No Warning letter followed
- Yes Form FDA 483 issued
- No Establishment inspection report (EIR) exists
- 1–9 Inspections at this FEI
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA inspections
FDA inspections are classified as No Action Indicated (NAI), Voluntary Action Indicated (VAI) or Official Action Indicated (OAI). Inspections of individual clinical investigators are not published here.
Source: U.S. Food and Drug Administration (FDA), inspection classification data